Alpha Pro Tech, Ltd. - 10-K Summary (Fiscal Year Ended Dec 31, 2003)
Business Context and Reporting Period
Company: Alpha Pro Tech, Ltd.
Reporting Period: Fiscal year ended December 31, 2003.
Business Overview: The Company develops, manufactures, and markets disposable protective apparel, infection control products (masks/shields), extended care products, and consumer pet products. Operations are organized into three segments: Apparel, Mask and Shield, and Extended Care. Manufacturing facilities are located in the U.S. (Utah, Wisconsin, Arizona, Georgia) and Mexico, with subcontracting in China.
Key Financial Metrics
| Metric | 2003 | 2002 |
|---|---|---|
| Net Sales | $26,961,000 | $21,789,000 |
| Gross Profit | $13,660,000 | $10,523,000 |
| Gross Margin | 50.7% | 48.3% |
| Net Income | $3,011,000 | $1,665,000 |
| Diluted EPS | $0.13 | $0.07 |
| Cash & Equivalents | $3,427,000 | $2,879,000 |
| Working Capital | $10,261,000 | $7,050,000 |
| Total Debt | $0 | $415,000 |
| Operating Cash Flow | $1,295,000 | $3,028,000 |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 23.7% to $26.96 million. Approximately $3.5 million of this increase was driven by non-core SARS-related sales of N-95 masks and eye shields. Excluding SARS sales, core business growth was 7.7%.
- Profitability: Net income surged 80.8% to $3.01 million, driven by higher gross margins (improved by increased Chinese manufacturing and higher-margin mask sales) and operational leverage.
- Segment Performance:
- Apparel: Sales up 8.6% to $16.1 million, driven by pharmaceutical industry growth, offset by weakness in the electronics/semiconductor sector.
- Mask and Shield: Sales up 84.5% to $9.0 million, primarily due to the SARS outbreak.
- Extended Care: Sales declined 10.6% to $1.9 million due to lower pet bed pad sales.
- Debt Reduction: The Company paid off all term and equipment loans ($415,000) during 2003 and ended the year debt-free.
- Cash Flow: Operating cash flow decreased by $1.73 million compared to 2002, primarily due to increased inventory and accounts receivable build-up to support sales growth.
Guidance, Outlook, and Risks
- Outlook: Management expects continued growth in core businesses and anticipates strong demand for N-95 masks due to heightened infection control awareness, even if SARS does not resurface. Gross margins are expected to remain strong.
- Strategy: Focus on expanding the sales team (increased from 10 to 15 in 2003) and developing innovative products. The Company plans to invest approximately $500,000 in additional equipment in 2004.
- Key Risks:
- Customer Concentration: Sales to the largest distributor, VWR Scientific, represented 54.8% of total sales in 2003. The loss of this customer would have a material adverse effect.
- Foreign Operations: Manufacturing in Mexico and China exposes the Company to foreign currency exchange rate fluctuations.
- Market Volatility: Continued weakness in the semiconductor/electronics industry negatively impacts the Apparel segment.
- Unusual Items: The $3.5 million in SARS-related sales is considered non-core and temporary in nature.
Investor Verification Checklist
- Distributor Dependency: Verify the status of the exclusive distribution agreement with VWR Scientific and the stability of this 54.8% revenue concentration.
- SARS Sales Sustainability: Assess the proportion of Q4 2003 sales attributable to SARS-related products versus core recurring demand.
- Inventory Levels: Review the significant increase in inventory ($2.66 million increase in 2003) to ensure it aligns with demand and does not indicate obsolescence risk.
- Debt-Free Status: Confirm the Company's ability to maintain liquidity without debt financing given the upcoming credit facility expiration in May 2004.
- Executive Compensation: Note the $500,000 executive bonus accrued in 2003 (10% of pre-tax profits), which impacts net income volatility.